Research graph
References from Differential risk signals of cutaneous adverse drug reactions among β-lactam antibiotics: ceftriaxone shows increased signals for SJS/TEN in clinical and real-world cohorts. Local targets link to admitted publications; unresolved targets remain external evidence.
Clinical and pathogenic aspects of the severe cutaneous adverse reaction epidermal necrolysis (EN)
10.1111/jdv.16339 · 2020 · External reference
Clinical practice. Exanthematous drug eruptions
10.1056/nejmcp1104080 · 2012 · External reference
SCORTEN: a severity-of-illness score for toxic epidermal necrolysis
10.1046/j.1523-1747.2000.00061.x · 2000 · External reference
Drug hypersensitivity reactions
10.1016/j.iac.2022.10.005 · 2023 · External reference
Drugs and the skin: a concise review of cutaneous adverse drug reactions
10.1111/bcp.15490 · 2024 · External reference
Epidemiology of cutaneous adverse drug reactions
10.5414/alx01508e · 2017 · External reference
Polypharmacy-an upward trend with unpredictable effects
10.3238/arztebl.2016.0627 · 2016 · External reference
Cutaneous drug reactions: classification, diagnosis, clinical and therapeutic consequences
10.1007/s40629-025-00350-y · 2025 · External reference
Developments in life expectancy in Germany. Current trends
10.25646/5873 · 2019 · External reference
Histopathologic features of maculopapular drug eruption
10.3390/dermatopathology9020014 · 2022 · External reference
Guideline for allergological diagnosis of drug hypersensitivity reactions
10.5414/alx02422e · 2023 · External reference
Update on Stevens–Johnson syndrome and toxic epidermal necrolysis: diagnosis and management
10.1007/s40257-024-00889-6 · 2024 · External reference
DRESS Syndrome: a literature review and treatment algorithm
10.1016/j.waojou.2022.100673 · 2023 · External reference
Drug allergy: a 2022 practice parameter update
10.1016/j.jaci.2022.08.028 · 2022 · External reference
Severe cutaneous adverse reactions to drugs: a real-world pharmacovigilance study using the FDA adverse event reporting system database
10.3389/fphar.2023.1117391 · 2023 · External reference
Drug-induced severe cutaneous adverse reactions: determine the cause and prevention
10.1016/j.anai.2019.08.004 · 2019 · External reference
Adverse drug reactions and organ damage: the skin
10.1016/j.ejim.2015.11.017 · 2016 · External reference
Mild cutaneous reactions to drugs
10.23750/abm.v90i3-s.8159 · 2019 · External reference
A systematic review of symmetrical drug-related intertriginous and flexural exanthema
10.1016/j.jdrv.2025.07.007 · 2025 · External reference
Erythema multiforme
10.1016/j.eclinm.2024.102909 · 2024 · External reference
Lichenoid drug reactions
10.1007/s00105-017-4117-y · 2018 · External reference
Identifying prognostic factors for drug rash with eosinophilia and systemic symptoms (DRESS)
10.1684/ejd.2011.1550 · 2011 · External reference
Clinicopathological features and prognosis of drug rash with eosinophilia and systemic symptoms: a study of 30 cases in Taiwan
10.1111/j.1468-3083.2008.02585.x · 2008 · External reference
Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death?
10.1001/archderm.136.3.323 · 2000 · External reference
Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study
10.1038/sj.jid.5701033 · 2008 · External reference
Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study
10.1111/bjd.12501 · 2013 · External reference
Antibiotic drug use and the risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: a population-based case-control study
10.1016/j.jid.2017.12.015 · 2018 · External reference
Worldwide prevalence of antibiotic-associated Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis
10.1001/jamadermatol.2022.6378 · 2023 · External reference
Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme
10.1001/archderm.1993.01680220104023 · 1993 · External reference
Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study
10.1001/archderm.138.8.1019 · 2002 · External reference
Acute generalized exanthematous pustulosis (AGEP)–a clinical reaction pattern
10.1034/j.1600-0560.2001.028003113.x · 2001 · External reference
A comprehensive review of methodologies and application to use the real-world data and analytics platform TriNetX
10.3389/fphar.2025.1516126 · 2025 · External reference
Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with anticonvulsants in a Japanese population: matched case–control and cohort studies
10.1016/j.alit.2021.01.004 · 2021 · External reference
Viral triggers exposed: a systematic review of virus-induced Stevens-Johnson syndrome/toxic epidermal necrolysis
10.2147/jir.s546186 · 2025 · External reference
Retrospective study of 213 cases of Stevens-Johnson syndrome and toxic epidermal necrolysis from China
10.1016/j.burns.2019.10.008 · 2020 · External reference
Stevens-Johnson syndrome and toxic epidermal necrolysis: analysis of the Russian database of spontaneous reports
10.3390/ph17060675 · 2024 · External reference
